Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
04/2003
04/01/2003US6540982 Medical aerosol formulation
04/01/2003US6540980 Method of detecting endometriosis
04/01/2003US6540978 Inhibitors of the bitter taste response
04/01/2003US6540977 Cyanidin compositions and therapeutic and diagnostic uses therefor
04/01/2003US6540715 Method and device for in-situ formulation of a medicinal solution for parenteral application
04/01/2003CA2044676C Pharmaceutical composition for rectal administration of active principles exhibiting a prevalently topical medication action at the colon level
03/2003
03/28/2003CA2405342A1 Methods of treatment and kits comprising a growth hormone secretagogue
03/28/2003CA2404723A1 Methods related to the a-c repeat z-sequence upstream from the aldose reductase gene
03/27/2003WO2003029411A2 Novel cyclooxygenase variants and methods of use
03/27/2003WO2003025542A2 Immune response associated proteins
03/27/2003WO2003025200A2 Methods of using 22417, a novel human aminoprotease family member
03/27/2003WO2003025199A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor
03/27/2003WO2003025193A1 Plant enzymes for bioconversion
03/27/2003WO2003025150A2 Lipid-associated molecules
03/27/2003WO2003025131A2 Protein modification and maintenance molecules
03/27/2003WO2003025129A2 Neurotransmission-associated proteins
03/27/2003WO2003025121A2 Igf-binding protein-derived peptide or small molecule
03/27/2003WO2003025019A1 Anti-pdgf antibodies and methods for producing engineered antibodies
03/27/2003WO2003025017A1 Cytokine receptor
03/27/2003WO2003024967A2 Indolizines as kinase protein inhibitors
03/27/2003WO2003024960A1 Novel use of substituted aminomethyl chromans
03/27/2003WO2003024950A1 Coumarin derivative
03/27/2003WO2003024941A1 Naphthalene compounds and use thereof as drugs
03/27/2003WO2003024489A2 Combination of a nsaid and a pde-4 inhibitor
03/27/2003WO2003024488A2 Combination of a pde inhibitor and a leukotriene receptor antagonist
03/27/2003WO2003024487A1 Method of increasing the presence of glutathione in cells
03/27/2003WO2003024481A2 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
03/27/2003WO2003024479A1 Enamel matrix protein compositions for modulating immune response
03/27/2003WO2003024473A2 Retinoid receptor pan-antagonists for stimulating chondrogenesis
03/27/2003WO2003024459A1 Protopanaxadiol and protopanaxatriol and their use as synergistic anti-cancer agents
03/27/2003WO2003024457A1 Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy
03/27/2003WO2003024456A1 Methods for treating and preventing migraines
03/27/2003WO2003024449A1 Pharmaceutical formulations for protecting pharmaceutical compound from acidic environments
03/27/2003WO2003024446A1 Oxidation stress inhibitor and method of measuring oxidation stress
03/27/2003WO2003024445A1 Drugs comprising combination of antithrombotic agent with pyrazolone derivative
03/27/2003WO2003024442A2 Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease
03/27/2003WO2003024439A1 Phenethanolamine derivatives for treatment of respiratory diseases
03/27/2003WO2003024436A2 Method for treating skin disorders
03/27/2003WO2003024420A1 Ophthalmic depot formulations for periocular or subconjunctival administration
03/27/2003WO2003024405A2 Methods and compositions for inhibiting the proliferation of prostate cancer cells
03/27/2003WO2003024404A2 Chemokines as adjuvants of immune response
03/27/2003WO2003024403A2 Carbohydrate supplementation and rehydration composition
03/27/2003WO2003024391A2 Treatment and prevention of mucositis in cancer patients
03/27/2003WO2003024386A2 Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
03/27/2003WO2003024357A2 Microfabricated nanopore device for sustained release of therapeutic agent
03/27/2003WO2003002058A8 Bone anabolic compounds and methods of use
03/27/2003WO2002100352A3 Nr2b receptor antagonists for the treatment or prevention of migraines
03/27/2003WO2002098889A3 MAP3Ks AS MODIFIER OF THE p53 PATHWAY AND METHODS OF USE
03/27/2003WO2002098356A3 Ppp2cs as modifiers of the p53 pathway and methods of use
03/27/2003WO2002096358A3 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
03/27/2003WO2002094254A3 Abuse resistant pharmaceutical composition containing capsaicin
03/27/2003WO2002092003A3 Novel therapeutical quaternary ammonium compositions
03/27/2003WO2002091990A3 Prevention of addiction in pain management
03/27/2003WO2002089781A3 Methods of treating hyperlipidemia
03/27/2003WO2002078678A3 Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
03/27/2003WO2002067987A3 Combinations of a 5ht1 receptor agonist with an analgesic, and an anti-emetic and/or a gastroprokinetic agent
03/27/2003WO2002062377A3 Combined use of factor vii polypeptides and factor viii polypeptides
03/27/2003WO2002060879A3 Bacterial gyrase inhibitors and uses thereof
03/27/2003WO2002055544A3 Fibrin binding polypeptides useful inter alia in medical imaging processes
03/27/2003WO2002055100A3 Method and composition for inhibition of tumor growth and enhancing an immune response
03/27/2003WO2002053717A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
03/27/2003WO2002053100A3 Pharmaceutical dosage form for oral administration of low molecular weight heparin
03/27/2003WO2002053089A3 Stable skin conditioning compositions containing retinoid boosters
03/27/2003WO2002048358A3 Regulation of human chemokine-like receptor
03/27/2003WO2002034201A3 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy
03/27/2003WO2002033086A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
03/27/2003WO2002032416A3 Inhibition of emetic effect of metformin with 5-ht3 receptor antagonists
03/27/2003WO2002029060A3 Hematopoietin receptors hpr1 and hpr2
03/27/2003WO2002028381A3 Methods of inducing cancer cell death and tumor regression
03/27/2003WO2002026951A3 Oxidoreductases
03/27/2003WO2002026219A3 Otic microbial combinations for treatment of animals with ruptured tympanic membrane
03/27/2003WO2002026212A3 Microparticle compositions and methods for the manufacture thereof
03/27/2003WO2002024892A3 Isolated human g-protein coupled receptors, nucleic acid molecules encoding them, and uses thereof
03/27/2003WO2002022684A3 Transporters and ion channels
03/27/2003WO2002019999A3 Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant
03/27/2003WO2002017880A3 Nitric oxide-producing hydrogel materials
03/27/2003WO2002015932A9 Methods for treating demyelinating diseases
03/27/2003WO2002013802A3 Method of treating estrogen receptor positive carcinoma
03/27/2003WO2002012340A3 Transporters and ion channels
03/27/2003WO2002005857A3 Phosphatonin-related gene and methods of use thereof
03/27/2003WO2001062954A3 Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
03/27/2003US20030060873 Providing an electrochemical solution comprising metal and bioactive material; contacting electrochemical solution and substrate; forming a bioactive composite structure on substrate using an electrochemical procedure
03/27/2003US20030060695 Implantable artificial organ devices
03/27/2003US20030060613 Protein for use in the treatment of bone, tumor and inflammatory disorders
03/27/2003US20030060515 Protein tyrosine kinase inhibitors for treating osteoarthritis
03/27/2003US20030060513 First compound selected from muscarinic receptor antagonists, 5-alpha-reductase inhibitors, and alpha-adrenergic receptor antagonists, second compound selected from 5-HT1a receptor agonists and antagonists; urinary disorders
03/27/2003US20030060510 Administering to the patient a compound capable of reducing glutamate-induced retinal cell migration in a concentration effective to reduce such migration
03/27/2003US20030060492 Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use
03/27/2003US20030060489 Administering an insulin sensitiser (a thiazolidinedione) and an agent used in treatment of cardiac condition associated with diabetes is beta-locker, an ACE inhibitor or diuretic
03/27/2003US20030060488 Drug comprising combination
03/27/2003US20030060487 Useful for treatments for peptide aggregation associated with disease state such as Alzhemimer's diseases
03/27/2003US20030060485 (+)-norcisapride
03/27/2003US20030060480 Farnesyl protein transferase inhibitor combinations with vinca alkaloids
03/27/2003US20030060478 Treatment of dyskinesia
03/27/2003US20030060477 Administering to a patient a betablocker and a cholesterol-lowering agent to treat atherosclerosis, hyperpoproteinemia and hypercholesterolemia
03/27/2003US20030060470 Ortho, ortho-substituted nitrogen-containing bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparation comprising them
03/27/2003US20030060469 Use of substances that act as cascade inhibitors of the raf/mek/erk signal cascade, for producing a medicament to treat dna and rna viruses
03/27/2003US20030060450 Such as 4-(3-chlorophenyl)-6-((4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl) -methyl)-1-methyl-2(1H)quinoline for treating mammalian tumors via inhibiting farnesyl transferase
03/27/2003US20030060433 Reducing the severity of cancer
03/27/2003US20030060432 Antagonists of the oncogenic activity of the protein mdm2, and use thereof in the treatment of cancers
1 ... 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 ... 1151